PTC Therapeutics Q4 2022 Earnings Report $46.24 +0.99 (+2.19%) (As of 12/20/2024 05:16 PM ET) Earnings HistoryForecast PTC Therapeutics EPS ResultsActual EPS-$2.35Consensus EPS -$1.96Beat/MissMissed by -$0.39One Year Ago EPS-$2.03PTC Therapeutics Revenue ResultsActual Revenue$167.41 millionExpected Revenue$183.07 millionBeat/MissMissed by -$15.66 millionYoY Revenue Growth+1.30%PTC Therapeutics Announcement DetailsQuarterQ4 2022Date2/21/2023TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptPress ReleaseSEC FilingPTCT Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Crypto’s hidden gem + greatest crypto bull run in history = $$$? (Ad)You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.Click Here to get the full details about Crypto’s Hidden Gem PTC Therapeutics Earnings HeadlinesPTC Therapeutics submits NDA for vatiquinone in Friedreich ataxiaDecember 19 at 1:55 PM | markets.businessinsider.comPTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich AtaxiaDecember 19 at 8:00 AM | prnewswire.comWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.December 21, 2024 | Behind the Markets (Ad)PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 17, 2024 | prnewswire.comPTC Therapeutics (PTCT) Receives a Buy from RBC CapitalDecember 13, 2024 | markets.businessinsider.comCantor Fitzgerald says ‘aggressively’ buy uniQure, PTC TherapeuticsDecember 11, 2024 | markets.businessinsider.comSee More PTC Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like PTC Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PTC Therapeutics and other key companies, straight to your email. Email Address About PTC TherapeuticsPTC Therapeutics (NASDAQ:PTCT), a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.View PTC Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
